ArticleOncology reports2018
hsa‑miR‑24 suppresses metastasis in nasopharyngeal carcinoma by regulating the c‑Myc/epithelial‑mesenchymal transition axis.
Article in Oncology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.
- Prognostic significance of microRNA miR-24 in cancers: a meta-analysis.Bioengineered · 2021Pooled it
- MiR-24-3p as a prognostic indicator for multiple cancers: from a meta-analysis view.Bioscience reports · 2020Pooled it
- C-MYC as a key effector of WNT, PI3K/AKT, MAPK, and TGF-β signaling pathways in regulation of epithelial-mesenchymal transition during tumor metastasis.Cancer cell international · 2026Review
- MicroRNA Profiles Distinguishing Metastatic from Non-Metastatic Salivary Mucoepidermoid Carcinoma.Journal of clinical medicine · 2025Article
- Review
- Article
- Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis via a SERPINH1/c-Myc positive feedback loop.Molecular cancer · 2022Article
- The Role of Non-Coding RNAs in the Regulation of the Proto-Oncogene MYC in Different Types of Cancer.Biomedicines · 2021Review
- MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distant metastasis is the major contributor to treatment failure and mortality in patients with nasopharyngeal carcinoma (NPC). The lack of effective treatment strategies for metastatic NPC is the major cause for the low survival rate. Therefore, it is crucial to understand the molecular mechanisms underlying NPC metastasis and to identify potential biomarkers for targeted therapy. MicroRNA (miRNAs or miRs) have been shown to play an important role in tumorigenesis and metastasis. In the present study, we aimed to evaluate the significance of hsa‑miR‑24 in NPC metastasis. Significantly lower hsa‑miR‑24 levels were observed in NPC metastatic tumors and higher hsa‑miR‑24 levels were associated with longer progression‑free and metastasis‑free survival durations. hsa‑miR‑24 overexpression inhibited cell proliferation, invasion and migration. Using bioinformatics approaches together with functional luciferase reporter assays, we demonstrated that the c‑Myc 3'‑UTR was a direct target of hsa‑miR‑24 in regulating NPC metastasis. Protein profiling analysis revealed that a high c‑Myc expression was inversely associated with metastasis‑free overall survival and with epithelial‑mesenchymal transition (EMT). Furthermore, the overexpression of hsa‑miR‑24 decreased NPC cell invasive ability induced by the overexpression of c‑Myc, associated with EMT epithelial marker (E‑cadherin) restoration. Thus, on the whole, the findings of this study demonstrate that hsa‑miR‑24 suppresses metastasis in NPC by regulating the c‑Myc/EMT axis, suggesting that hsa‑miR‑24 may be used as a prognostic factor and as a novel target for the prevention of NPC metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.